WO1994014406A1 - Oral compositions containing antiplaque, anticalculus agents - Google Patents

Oral compositions containing antiplaque, anticalculus agents Download PDF

Info

Publication number
WO1994014406A1
WO1994014406A1 PCT/US1993/011786 US9311786W WO9414406A1 WO 1994014406 A1 WO1994014406 A1 WO 1994014406A1 US 9311786 W US9311786 W US 9311786W WO 9414406 A1 WO9414406 A1 WO 9414406A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
zinc
compositions
oral
ions
Prior art date
Application number
PCT/US1993/011786
Other languages
French (fr)
Inventor
Ronald Earl Montgomery
Angela Marie Maddux
Matthew Edward Volpenhein
Vrinda Ramchandra Shanbhag
Original Assignee
The Procter & Gamble Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter & Gamble Company filed Critical The Procter & Gamble Company
Priority to BR9307689-4A priority Critical patent/BR9307689A/en
Priority to AU57399/94A priority patent/AU5739994A/en
Priority to JP6515184A priority patent/JPH08504816A/en
Priority to EP94903458A priority patent/EP0675705A1/en
Publication of WO1994014406A1 publication Critical patent/WO1994014406A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/24Phosphorous; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/27Zinc; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365Hydroxycarboxylic acids; Ketocarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis

Definitions

  • This invention relates to oral compositions, such as dentifrices and oral solutions, for the treatment or prevention of dental plaque, calculus, gingivitis, and mouth malodor.
  • the mouth is a habitat for microbial growth and colonization.
  • the gums, lips, oral mucosa (cheek), palate, tongue and teeth provide surfaces for the colonization and accumulation of bacteria.
  • Teeth are unique in the oral cavity because they have hard, non-shedding surfaces where bacteria and their products (dental plaque) can significantly accumulate, especially in approximal areas and along the gingival crevice.
  • Dental plaque is a rough sticky film on the teeth that is made up of saliva, bacteria and food particles which adheres tenaciously to teeth at points of irregularity or discontinuity.
  • salivary mucins consisting primarily of proteins
  • Various oral bacteria colonize the mucins and multiply, forming a layer of plaque.
  • Carbohydrate food debris adheres to the mucins and is digested by some types of plaque- causing bacteria. The digestion produces both by-products which add to the plaque, and produces acid which erodes tooth enamel.
  • the bacterial by-products produced in the oral cavity also include foul smelling gases which can result in malodor of the oral cavity.
  • plaque may become embedded with mineral salts, containing calcium and phosphate, to form a hard crusty deposit, calculus or tartar, on the teeth.
  • Calculus may be white or yellowish in color or may be stained or discolored by extraneous agents. Calculus tends to be more unsightly than plaque and much more difficult to remove from the teeth.
  • the toxins in plaque and calculus can irritate the gingival tissues surrounding the coated teeth, causing inflammation and destruction of the gums which can lead to other complications.
  • Zinc is an anticalculus agent; however, compositions containing zinc generally taste astringent and unknowingly bitter. Like the chemical and biological activities, the negative aesthetics of the zinc cation are dose dependent: higher concentrations of zinc exhibit poorer aesthetics; therefore, increasing the concentration of free zinc tends to increase efficacy at the expense of aesthetics. This coupled behavior between efficacy and aesthetics has limited the utility of zinc in oral compositions. Pyrophosphate is also an anticalculus agent and, likewise, has an unpleasant taste which worsens with increased pyrophosphate concentration.
  • compositions effective against dental plaque formation, calculus formation, gingivitis, and mouth malodor comprise certain zinc salts and certain molar ratio amounts of citrate and pyro relative to zinc in a pharmaceutically- acceptable carrier.
  • Polyro refers to pyrophosphate; phosphonate; diphosphonate; and pharmaceutically-acceptable polyphosphates including, but not limited to, linear condensed polyphosphates of the wherein n is an integer from 2 to
  • “Pharmaceutically-acceptable topical oral carrier”, as used herein, denotes a carrier for the active compounds of this invention (hereinafter “Actives”) comprising solid or liquid filler diluents suitable for use in contact with the oral tissues of humans and other animals without undue, toxicity, incompatibility, instability, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio.
  • Actives a carrier for the active compounds of this invention
  • Such topical oral carrier when combined with Actives of this invention, results in a composition which is administered topically to the oral cavity.
  • Such compositions are held in the oral cavity for a period of time, and then largely expectorated rather than being swallowed.
  • Such compositions include mouthwashes, mouth rinses, mouth sprays, dental treatment solutions, toothpastes, liquid dentifrices and the like and are more fully described hereinafter. Dentifrices and mouthwashes are the preferred compositions.
  • Free pyro refers to pyro that is not bound or chelated to the transition metal, zinc.
  • Free zinc refers to hydrated zinc cationic species, such as Znfh OJ ⁇ 2"1" .
  • Safe and effective amount as used herein means an amount of compound or composition sufficient to induce a significant positive modification in the condition to be treated, but low enough to avoid serious side effects (at a reasonable benefit/risk ratio), within the scope of sound medical judgment.
  • the safe and effective amount of the compound or composition will vary with the particular condition being treated, the age and physical condition of the patient being treated, the severity of the condition, the duration of the treatment, the nature of concurrent therapy, the specific compound or composition employed, the particular pharmaceutically-acceptable carrier utilized, and like factors.
  • the term “comprising”, as used herein, means that various additional components can be conjointly employed in the compositions of this invention.
  • the amounts of pyro and citrate are expressed in terms of a ratio to the amount of zinc in the oral composition.
  • the amount of citrate relative to zinc is at least 0.1 when the amount of zinc is "1" (i.e. the ratio of zincxitrate is at most 1:0.1).
  • the amount of pyro relative to to the amount of zinc is at least 1 when zinc is 1 (i.e. the ratio of zinc:pyro is at most 1:1).
  • Preferred zincxitrate ratios are from about 1:0.1 to about 1:20, more preferably from about 1:0.5 to about 1:4, more preferably from about 1:1 to about 1:3.
  • Preferred zinc:pyro ratios are from about 1:1 to about 1:20, more preferably from about 1 :2 to about 1 :6, more preferably from about 1 :3 to about 1:5. Also preferred is a zincxitrate: pyro ratio wherein the sum of the ratio amounts of citrate and pyro is from about 3 to about 9, more preferably from about 4 to about 7, when the ratio amount of zinc is 1.
  • the amount of zinc suitable for the purposes of this invention is from about 0.005% to about 5% Zn; more preferably from about 0.05% to about 2% Zn; more preferably still from about 0.1% to about 0.6% Zn.
  • the preferred amounts of zinc are from about 0.1% to about 2%, more preferably from about 0.3% to about 0.6%.
  • the preferred amount of zinc is from about 0.005% to about 1%, more preferably from about 0.01% to about 0.75%, more preferably still from about 0.05% to about 0.5%.
  • the amount of citrate anion suitable for the purposes of this invention is from about 0.015% to about 15% citrate.
  • the preferred amounts of citrate anion are from about 0.2 % to about 8%, more preferably from about 0.4% to about 7%, more preferably still from about 0.6% to about 6%.
  • the preferred amount of citrate anion is from about 0.01% to about 12%, more preferably from about 0.1% to about 6%, more preferably still from about 0.15% to about 1 %.
  • the amount of pyro anion suitable for the purposes of this invention is from about 0.5% to about 15% pyro.
  • the preferred amounts of pyro ion are from about 1 % to about 9%, more preferably from about 2.5% to about 5%.
  • the preferred amount of pyro anion is from about 0.01% to about 25%, more preferably from about 0.1% to about 5%.
  • Suitable sources of zinc ions include zinc oxide and Zn(N03)2*
  • Zinc sources that are not suitable are zinc ethylenediaminetetraacetate (ZnEDTA) and zinc nitrilotriacetate (ZnNTA).
  • the preferred source of zinc ions is ZnO.
  • Suitable sources of citrate ions include citric acid; alkali metal salts of citric acid, especially sodium citrate and potassium citrate; pharmaceutically acceptable hydrated and dehydrated salts of any of the above; and mixtures of any of the above.
  • Suitable sources of pyro ions are disclosed in U.S. Pat. No. 4,885,155, issued December 5, 1989 to Parran & Sakkab; U.S. Pat. No. 3,678,154, issued July 18, 1972 to Widder et al.; U.S. Pat. No. 3,737,522, issued June 5, 1973 to Francis et al.; and U.S. Pat. No. 4,627,977, issued Dedember 9, 1986 to Gaffar et al.; each is incorporated herein by reference.
  • Suitable pyro ion sources include tetrasodium pyrophosphate, sodium acid pyrophosphate (Na2H2P2 ⁇ 7), tetrapotassium pyrophosphate (K4P2O7); phosphates including, but not limited to, linear condensed polyphosphates of the general M ' s Na or ⁇ .
  • n is an integer rom to ; p osphonates and diphosphonates, such as EHDP (ethane-1-hydroxy-1,1-diphosphonate) and AHP (azacyclo- heptane-2,2-diphosphonic acid); pharmaceutically-acceptable alkali metal salts of pyrophosphates, polyphosphates, phosphonates and diphosphonates; and mixtures of any of the above.
  • Preferred polyphosphate ions are those of the above formula wherein n is 6, 13, and 21.
  • Preferred pyro ions are pyrophosphate ions.
  • Preferred alkali metals are sodium and potassium; mixtures of alkali metal salts are acceptable.
  • a more preferred source of pyro ions is a potassium salt of the pyro ion.
  • compositions Components of the topical, oral carrier are suitable for administration to the oral cavity of a human or other animal and are compatible with one another and the other components, especially with the Actives, used in an oral composition of this invention.
  • compatible means that the components are capable of being co-mingled with one another, in a manner such that there is no interaction which would substantially reduce the efficacy of the oral composition under ordinary use conditions.
  • Preferred topical, oral carriers provide the desired characteristics for mouthwashes, mouth rinses, mouth sprays, dental treatment solutions, toothpastes, dental gels, toothpowders, prophylaxis pastes, and the like.
  • the topical, oral carriers of this invention comprise components typically used in such compositions which are well known to a skilled practitioner.
  • Such components include, but are not limited to, anticaries agents, antiplaque agents, anticalculus agents, dental abrasives, surfactants, flavoring agents, sweetening agents, binders, humectants, thickening agents, buffering agents, preservatives, coloring agents and pigments, ethanol and water.
  • the pH of oral compositions of this invention is critical but can be varied to some extent.
  • the compositions must be at a pH which is safe for contact with the tissues of the. oral cavity, i.e. below a pH of about 9 for humans, preferably below a pH of about 8.5. Otherwise, the pH of the compositions is preferably above pH 6, more preferably above pH 7, more preferably still, above pH 7.5.
  • the conditions for addition of each component should be optimized such that the pH of the mixture does not drop below formulation pH at any time during mixing of the ingredients.
  • a pH of at least about 7.5 should be maintained at all times.
  • Water is a component of the topical, oral carriers of the compositions of the subject invention.
  • Water employed in the preparation of the commercially suitable compositions should preferably be of low ion content and free of organic impurities.
  • Water preferably comprises from about 2% to about 99%, more preferably from about 20% to about 95% of the compositions of the subject invention.
  • the compositions preferably comprise from about 20% to about 99.5%, more preferably from about 30% to about 99%, still more preferably from about 35% to about 98%, more preferably still from about 40% to about 97% water.
  • Mouthwashes comprise preferably from about 2% to about 99.5%, more preferably from about 45% to about 99%, more preferably still from about 75% to about 98%, water.
  • binders and/or thickening agents are those which are non-ionic at the formulation pH of the composition.
  • non-ionic is meant, not more than about 10% ionized.
  • formulation pH means the pH of the final composition.
  • Suitable binders include, but are not limited to, natural gums such as gum karaya, gum arabic, and gum tragacanth; polysaccharide gums such as xanthan gum; and other natural products such as carrageenan; chemically modified natural products such as those based on cellulose esters, that is, carboxylmethylcellulose (CMC), hydroxyethylcellulose (HEC), and hydroxypropylcellulose (HPC); and synthetic binders such as polyvinylpyrrolidone; and water soluble salts of cellulose ethers such as sodium carboxymethyl cellulose and sodium carboxymethyl hydroxyethyl cellulose.
  • Carboxyvinyl polymer binders are less desirable, but may be used.
  • colloidal magnesium aluminum silicate or finely divided silica can be used as part of the thickening agent to further improve texture.
  • Blends and mixtures of the suitable binders may significantly improve the characteristics of compositions made therewith.
  • Preferred binders are chemically modified celluloses such as CMC or HEC; more preferred is HEC.
  • Binders and thickening agents are generally present in the compositions of this invention in combined amounts of from about 0.1% to 10%, preferably from about 0.25% to about 7.5%, more preferably from about 0.5% to about 3.5%.
  • Optional Components are generally present in the compositions of this invention in combined amounts of from about 0.1% to 10%, preferably from about 0.25% to about 7.5%, more preferably from about 0.5% to about 3.5%.
  • Dental abrasives useful in the topical, oral carriers of the compositions of this invention include many different materials.
  • the material selected must be one which is compatible with the composition of interest and does not excessively abrade dentin.
  • These include, for example, silicas, including gels and precipitates, calcium carbonate, dicalcium orthophosphate dihydrate, calcium pyrophosphate, tricalcium phosphate, calcium polymeta-phosphate, insoluble sodium polymeta-phosphate, hydrated alumina, and resinous abrasive materials such as particulate condensation products of urea and formaldehyde, and other materials such as those disclosed by Cooley et al. in U.S. Pat. No. 3,070,510, issued December 25, 1962, incorporated herein by reference. Mixtures of abrasives may also be used.
  • Silica dental abrasives of various types, can provide the unique benefits of exceptional dental cleaning and polishing performance without unduly abrading tooth enamel or dentin. For this reason they are preferred for use herein.
  • the silica abrasive polishing materials useful herein, as well as the other abrasives generally have an average particle size ranging between about 0.1 and 30 microns, preferably between about 5 and 15 microns.
  • the silica abrasive can be precipitated silica or silica gels such as the silica xerogels described in U.S. Pat. No. 3,538,230, issued March 2, 1970 to Pader et al., and in U.S. Pat. No. 3,862,307, issued June 21, 1975 to DiGiulio, both incorporated herein by reference.
  • Preferred precipitated silica materials include those marketed by the J. M. Huber Corporation under the tradename, Zeodent®, particularly the silica carrying the designation Zeodent 119®. These silica abrasives are described in U.S. Pat. No. 4,340,583, Wason, issued July 20, 1982, incorporated herein by reference.
  • abrasives may be used.
  • the amount of abrasive in the compositions described herein ranges from about 6% to about 70%, preferably from about 15% to about 50%, more preferably from about 15% to about 30%, when the dentifrice is a toothpaste. Higher levels, as high as 90%, may be used if the composition is a tooth powder.
  • Flavoring agents can also be added to the oral compositions of this invention to make them more palatable. Suitable flavoring agents include menthol, oil of wintergreen, oil of peppermint, oil of spearmint, oil of sassafras, and oil of clove. Flavoring agents are generally included in the subject compositions in amounts of from 0% to about 3%, preferably from about 0.04% to about 2% by weight. Coloring agents may be added to compositions of this invention to improve appearance. If present, coloring agents typically are included at levels of from about 0.001% to about 0.5% by weight.
  • Sweetening agents are also preferred in the compositions of this invention to make them more palatable.
  • Sweetening agents which can be used include aspartame, acesulfame, saccharin salts, dextrose, glucose, levulose thaumatin, D-tryptophan, dihydrochalcones, and cyclamate salts. Saccharin salts are preferred.
  • Sweetening agents are generally used in the subject compositions in amounts of from 0% to about 6%, preferably from about 0.005% to about 5% by weight.
  • Oral compositions can also contain a surfactant.
  • Suitable surfactants are those which are reasonably stable and form suds throughout the pH range suitable for compositions of this invention, including nonsoap anionic, nonionic, cationic, zwitterionic and amphoteric organic synthetic detergents, and compatible mixtures thereof. Many of these suitable surfactants are disclosed in U.S. Pat. No. 4,051,234, issued to Gieske et al. on September 27, 1977, and in U.S. Pat. No. 3,959,458 issued to Agricola, Briner, Granger and Widder on May 25, 1976, both of which are incorporated herein by reference.
  • Surfactants are typically present in compositions of this invention at a level of from 0% to about 20%, preferably from about 0.1, more preferably from about 1% to about 4% by weight. Surfactants may also be used as solubilizing agents to help retain sparingly soluble components, e.g., some flavoring agents, in solutions. Surfactants suitable for this purpose include polysorbates and poloxamers.
  • humectant serves to keep toothpaste compositions from hardening upon exposure to air, and to give mouthwash and toothpaste compositions a moist feel to the mouth. Certain humectants can also impart desirable sweetness of flavor to mouthwash and toothpaste compositions.
  • the humectant on a pure humectant basis, generally comprises from 0% to about 70%, preferably from about 2% to about 55%, by weight of the compositions herein.
  • Suitable humectants for use in compositions of this invention include edible polyhydric alcohols such as glycerin, sorbitol, xylitol, polyethylene glycol, and propylene glycol, especially sorbitol and glycerin.
  • Preferred humectants are sorbitol and glycerin; more preferred is sorbitol.
  • Opacifiers may also be used in toothpastes of this invention to render the toothpaste opaque.
  • Suitable opacifiers include titanium dioxide and some abrasives including, for example, magnesium aluminum silicate. Opacifiers generally comprise from 0% to about 4%, preferably from about 0.5% to about 3% by weight of the compositions herein.
  • Other optional components of the compositions of this invention are preservatives. The preservatives prevent microbial growth in the compositions. Suitable preservatives include methylparaben, propylparaben, benzoates and ethanol. If the preservative is ethanol, it generally comprises from 0% to about 35% by weight, preferably from about 5% to about 15%, of the compositions herein. Other preservatives generally comprise from 0% to about 5% by weight, preferably from about 0.08% to about 2%, of the compositions herein.
  • Antimicrobial, antiplaque agents can also optionally be present in the oral compositions of this invention, on the condition that they are compatible with the Actives.
  • Such agents may include, but are not limited to, triclosan, 2,4,4'-trichloro-2 , -hydroxydiphenyl ether, as described The Merck Index. 11th Ed. (1989), p. 1520 (entry No. 9573); chlorhexidine, .Merck Index. No. 2090); alexidine (Merck Index. No. 222); hexetidine (Merck Index. No. 4624); sanguinarine (Merck Index. No. 8320); benzalkonium chloride (Merck Index. No. 1066); salicylanilide (Merck Index. No.
  • the antimicrobial antiplaque agents may comprise from 0% to about 6%, preferably from about 0.1% to about 5% by weight of the compositions of this invention.
  • Bleaching agents can also be present in the oral compositions of this invention.
  • Suitable bleaching agents include organic and inorganic oxidizing agents such as hydrogen peroxide, alkali metal peroxides and superoxide and organic peroxides such as monoper- oxyphthalates and perbenzoic derivatives. If present, such bleaching agents may comprise from 0% to about 6%, preferably from about 1 % to about 5% by weight of the compositions of this invention.
  • Nutrients can also be present in the oral composition of this invention, on condition that they are compatible with the Actives. Such agents may include folate, retinoids (Vitamin A), Vitamin C, Vitamin E. If present, the nutrients generally comprise from about 0.001% to about 10% by weight of the compositions of this invention.
  • a fluoride ion source typically is in the form of a water-soluble fluoride compound.
  • This water-soluble fluoride compound is typically present in the compositions of this invention in an amount sufficient to give a fluoride concentration of from about 0.0025% to about 5.0% by weight, preferably from about 0.005% to about 2.0% by weight.
  • Preferred fluoride sources are sodrum fluoride, acidulated phosphate fluoride, and sodium monofluorophosphate.
  • polysaccharides include synthetic or natural anionic polymeric polycarboxylates, polysaccharides, and polysulfates.
  • the polymers may be present at a weight amount of from about 0.05% to about 3%, more preferably form about 0.05% to about 2%, more preferably still from about 0.1% to about 2%.
  • Suitable polymers include but are not limited to copolmers of maleic acid anhydride or acid with another polymerizable ethylenically unsaturated monomers, linear polycarboxylates, alginates, pectins, carageenans.
  • copolymers of maleic anhydride or acid with another polymerizable ethylenically unsaturated monomer preferably methyl vinyl ether (methoyethylene) having a molcular weight (M.W.) of about 30,000 to about 1,000,000.
  • M.W. molcular weight
  • copolymers are available for example as Gantrez® AN 139 (M.W. 500,000), A.N. 119 (M.W. 250,000) and preferably S-97 Pharmaceutical Grade (M.W. 70,000), of GAF Co ⁇ oration.
  • Other operative polymeric polycarboxylates include those disclosed in U.S. Pat. No.
  • 3,956,480 such as the 1:1 copolymers of maleic anhydride with ethyl acrylate, hydroxyethyl methacrylate, N- vinyl-2-pyrrolidone, or ethylene, the latter being available for example as Monsanto EMA No. 1103, M.W. 10,000, and EMA Grade 61 , and 1:1 copolymers of acrylic acid with methyl or hydroxyethyl methacrylate, methyl or ethyl acrylate, isobutyl vinyl ether or N-vinyl 2- pyrrolidone.
  • Preferred Compositions such as the 1:1 copolymers of maleic anhydride with ethyl acrylate, hydroxyethyl methacrylate, N- vinyl-2-pyrrolidone, or ethylene, the latter being available for example as Monsanto EMA No. 1103, M.W. 10,000, and EMA Grade 61 , and 1:1 copolymers of acrylic acid with methyl or hydroxyethyl methacrylate
  • compositions of this invention are in the form of dentifrices, especially toothpastes.
  • Components of toothpastes generally include a dental abrasive (from about 10% to about 50%), a surfactant (from about 0.5% to about 10%), a thickening agent (from about 0.1% to about 5%), a humectant (from about 10% to about 70%), a flavoring agent (from about 0.04% to about 2%), a sweetening agent (from about 0.1% to about 3%), a coloring agent (from about 0.01 % to about 0.5%) and water (from about 2% to about 45%).
  • Other preferred compositions of this invention are mouthwashes, mouth sprays, and dental solutions.
  • compositions of such mouthwashes and mouth sprays include water (from about 45% to about 99%), ethanol (from 0% to about 25%), humectant (from 0% to about 50%), surfactant (from about 0.01% to about 7%), flavoring agent (from about 0.04% to about 2%), sweetening agent (from about 0.1% to about 3%), and coloring agent (from about 0.001% to about 0.5%).
  • Such mouthwashes and mouth sprays may also include an antiplaque agent (from about 0.1% to about 5%).
  • Another aspect of this invention involves methods of treating or preventing mouth odor, dental plaque, calculus and gingivitis, by application of compositions comprising a safe and effective amount of Actives, to tissues of the oral cavity.
  • compositions comprising a safe and effective amount of Actives, to tissues of the oral cavity.
  • methods of these invention involve administering a safe and effective amount of Actives, preferably by administering an oral composition of this invention, as described hereinabove, to the oral cavity.
  • methods of this invention comprise administering an amount of composition comprising at least about 0.001 g of the Actives.
  • the teeth and other oral cavity tissues are exposed to the Actives.
  • the oral composition is a toothpaste
  • a toothpaste preferably from about 0.3 grams to about 15 grams, preferably from about 0.5 grams to about 5 grams, more preferably from about 1 to about 2 grams
  • an applicating device e.g., a toothbrush.
  • the applicating device is then contacted with the oral cavity surfaces in a manner such that the oral composition is contacted with tissue of the oral cavity, especially the teeth and gums.
  • the applicating device may be further used to effect an even distribution of the oral composition to the tooth surface, for example by brushing.
  • the application preferably lasts for a period of from about 15 seconds to about 10 minutes, more preferably from about 30 seconds to about 3 minutes, more preferably still from about 1 minute to about 2 minutes.
  • the toothpaste residue is typically removed from the tooth surface by using a liquid acceptable to the oral cavity, typically water, to rinse and be expectorated from the oral cavity.
  • a liquid acceptable to the oral cavity typically water
  • the oral composition is a mouthwash, typically from about 1 ml. to about 20 ml., preferably from about 2 ml. to about 15 ml., most preferably from about 10 ml. to about 15 ml., of liquid mouthwach containing the antiplaque Active is introduced to the oral cavity.
  • the liquid mouthwash is then agitated for from about 10 seconds to about 10 min., preferably from about 15 seconds to about 3 min., more preferably from about 30 seconds to about 2 minutes, within the oral cavity to obtain an improved distribution of the mouthwash over the tissue of the oral cavity.
  • the mouthwash is typically expectorated from the oral cavity.
  • Application frequency is preferably from about 3 times weekly to about 4 times daily, more preferably from about once daily to about 3 times daily, more preferably still from about once to about twice daily.
  • the period of treatment typically ranges from about one day to a lifetime.
  • compositions of this invention can be made using methods which are commonly used to produce oral care products.
  • EXAMPLES l-VI The following are examples of dentifrice compositions of this invention and are made using conventional processes. The numbers listed are weight percentages of the compositions. During manufacture, the pH is maintained at a minimum of pH 7.5.
  • EXAMPLE VII Following dental prophylaxis, a person brushes his teeth for sixty seconds twice daily using 1 g of a fluoride, non-anticalculus toothpaste. After eight weeks he receives dental prophylaxis performed by his dentist. For the following eight weeks the person brushes his teeth for sixty seconds twice daily with 1 g of the composition of Example I. After eight weeks, the person has significantly less calculus on his teeth than he did after the first eight weeks.
  • a person brushes his teeth for sixty seconds twice daily using 1 g of a fluoride, non-anticalculus toothpaste. After one week he receives dental prophylaxis performed by his dentist. For the following week the person brushes his teeth for sixty seconds twice daily with 1 g of the composition of E ⁇ xample IV. After one week, the person has significantly less plaque on his teeth than he did after the first week.
  • EXAMPLE IX Following dental prophylaxis, a person brushes his teeth for sixty seconds twice daily using 1.5 g of a fluoride, non-anticalculus toothpaste. After nine weeks he receives dental prophylaxis performed by his dentist. For the following nine weeks the person brushes his teeth for sixty seconds twice daily with 1.5 g of the composition of Example III. After nine weeks, the person has significantly less calculus on his teeth than he did after the first nine weeks.
  • EXAMPLE XV Following dental prophylaxis, a person rinses her mouth for twenty seconds twice daily for a period of eight weeks using 10 ml of a non-anticalculus mouth rinse. After eight weeks, the person received dental prophylaxis and rinses for twenty seconds twice daily with 10 ml of the composition of Example XI. After eight weeks, the person has significantly less calculus on her teeth than she did after the first eight weeks, using the non-anticalculus mouth rinse.
  • EXAMPLE XVI Following dental prophylaxis, a person rinses her mouth for thirty seconds twice daily for a period of one week using 12 ml of a non-antiplaque mouth rinse. During this week, the person does not brush her teeth. At the end of one week, the person received dental prophylaxis and rinses for thirty seconds twice daily with 12 ml of the composition of Example XIII. During this week, the person does not brush her teeth. At the end of one week, the person has significantly less plaque on her teeth than she did after the first week, using the non-antiplaque mouth rinse.
  • EXAMPLE XVII Following dental prophylaxis, a person rinses her mouth for forty-five seconds twice daily for a period of nine weeks using 15 ml of a non-anticalculus mouth rinse. After nine weeks, the person received dental prophylaxis and rinses for forty-five seconds twice daily with 15 ml of the composition of Example XIV. After nine weeks, the person has significantly less calculus on her teeth than she did after the first nine weeks, using the non-anticalculus toothpaste.

Abstract

This invention involves oral-care compositions, comprising: (a) zinc oxide or zinc nitrate; a source of citrate ions; and one or more phosphorous-containing anticalculus agents selected from the group consisting of pyrophosphate, phosphonate, diphosphonate and pharmaceutically-acceptable linear condensed polyphosphates of the general formula: (PnO(3n+1)(n+2)- wherein n is an integer from 2 to 21; wherein the molar ratio of the zinc ions:citrate ions if from about 1.01 to about 1:20; the molar ratio of the zinc ions:phosphorus-containing anticalculus agents is from about 1:1 to about 1:20; and (b) a pharmaceutically-acceptable topical oral carrier. This invention also involves methods for treating or preventing dental plaque, calculus, gingivitis, or malodor of the oral cavity comprising amdinistering to the oral cavity of a human or other animal a safe and effective amount of such compositions.

Description

ORAL COMPOSITIONS CONTAINING ANTIPLAQUE, ANTICALCULUS AGENTS
This invention relates to oral compositions, such as dentifrices and oral solutions, for the treatment or prevention of dental plaque, calculus, gingivitis, and mouth malodor.
Background of the Invention The mouth is a habitat for microbial growth and colonization. Within the mouth, the gums, lips, oral mucosa (cheek), palate, tongue and teeth provide surfaces for the colonization and accumulation of bacteria. Teeth are unique in the oral cavity because they have hard, non-shedding surfaces where bacteria and their products (dental plaque) can significantly accumulate, especially in approximal areas and along the gingival crevice.
Dental plaque is a rough sticky film on the teeth that is made up of saliva, bacteria and food particles which adheres tenaciously to teeth at points of irregularity or discontinuity. Within a few hours of teeth cleaning, a film of salivary mucins, consisting primarily of proteins, forms on the teeth. Various oral bacteria colonize the mucins and multiply, forming a layer of plaque. Carbohydrate food debris adheres to the mucins and is digested by some types of plaque- causing bacteria. The digestion produces both by-products which add to the plaque, and produces acid which erodes tooth enamel. The bacterial by-products produced in the oral cavity also include foul smelling gases which can result in malodor of the oral cavity. If not prevented or removed, plaque may become embedded with mineral salts, containing calcium and phosphate, to form a hard crusty deposit, calculus or tartar, on the teeth. Calculus may be white or yellowish in color or may be stained or discolored by extraneous agents. Calculus tends to be more unsightly than plaque and much more difficult to remove from the teeth. The toxins in plaque and calculus can irritate the gingival tissues surrounding the coated teeth, causing inflammation and destruction of the gums which can lead to other complications.
Zinc is an anticalculus agent; however, compositions containing zinc generally taste astringent and unpleasantly bitter. Like the chemical and biological activities, the negative aesthetics of the zinc cation are dose dependent: higher concentrations of zinc exhibit poorer aesthetics; therefore, increasing the concentration of free zinc tends to increase efficacy at the expense of aesthetics. This coupled behavior between efficacy and aesthetics has limited the utility of zinc in oral compositions. Pyrophosphate is also an anticalculus agent and, likewise, has an unpleasant taste which worsens with increased pyrophosphate concentration. By carefully formulating zinc and pyrophosphate-containing compositions, it has been surprisingly found that the level of zinc in an oral composition can be increased, thus increasing the corresponding anticalculus effect, without greatly increasing the negative aesthetics of the composition. Applicants have surprisingly found that certain ratios of zinc:citrate:pyrophosphate in combination with certain formulation components unexpectedly provide oral compositions which are stable for longer time periods than are other formulations.
Summary of the Invention This invention involves oral-care compositions comprising:
(a) zinc oxide or zinc nitrate; a source of citrate ions; and one or more phosphorus-containing anticalculus agents selected from the group consisting of pyrophosphate, phosphonate, diphosphonate and pharmaceutically- acceptable linear condensed polyphosphates of the general formula: (PnO(3n+-j))(n+2)- wherein n is an integer from 2 to 21 ; wherein a molar ratio of the zinc ionsxitrate ions is from about 1 :0.1 to about 1:20; the molar ratio of the zinc ions:phosphorus-containing anticalculus agents is from about 1:1 to about 1:20; and
(b) the pharmaceutically-acceptable topical oral carrier. Detailed Disclosure of the Invention This invention provides compositions effective against dental plaque formation, calculus formation, gingivitis, and mouth malodor. Such compositions comprise certain zinc salts and certain molar ratio amounts of citrate and pyro relative to zinc in a pharmaceutically- acceptable carrier.
"Pyro", as used herein, refers to pyrophosphate; phosphonate; diphosphonate; and pharmaceutically-acceptable polyphosphates including, but not limited to, linear condensed polyphosphates of the wherein n is an integer from 2 to
Figure imgf000005_0001
"Pharmaceutically-acceptable topical oral carrier", as used herein, denotes a carrier for the active compounds of this invention (hereinafter "Actives") comprising solid or liquid filler diluents suitable for use in contact with the oral tissues of humans and other animals without undue, toxicity, incompatibility, instability, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio. Such topical oral carrier, when combined with Actives of this invention, results in a composition which is administered topically to the oral cavity. Preferably such compositions are held in the oral cavity for a period of time, and then largely expectorated rather than being swallowed. Such compositions include mouthwashes, mouth rinses, mouth sprays, dental treatment solutions, toothpastes, liquid dentifrices and the like and are more fully described hereinafter. Dentifrices and mouthwashes are the preferred compositions.
"Free pyro", as used herein, refers to pyro that is not bound or chelated to the transition metal, zinc.
"Free zinc", as used herein, refers to hydrated zinc cationic species, such as Znfh OJβ2"1". "Safe and effective amount" as used herein means an amount of compound or composition sufficient to induce a significant positive modification in the condition to be treated, but low enough to avoid serious side effects (at a reasonable benefit/risk ratio), within the scope of sound medical judgment. The safe and effective amount of the compound or composition will vary with the particular condition being treated, the age and physical condition of the patient being treated, the severity of the condition, the duration of the treatment, the nature of concurrent therapy, the specific compound or composition employed, the particular pharmaceutically-acceptable carrier utilized, and like factors. The term "comprising", as used herein, means that various additional components can be conjointly employed in the compositions of this invention.
As used herein, percentages listed are weight percentage of composition unless otherwise specified. Zinc: Citrate and Zinc:Pyro Ratios
The amounts of pyro and citrate are expressed in terms of a ratio to the amount of zinc in the oral composition. On a molar basis, the amount of citrate relative to zinc is at least 0.1 when the amount of zinc is "1" (i.e. the ratio of zincxitrate is at most 1:0.1). Likewise, the amount of pyro relative to to the amount of zinc is at least 1 when zinc is 1 (i.e. the ratio of zinc:pyro is at most 1:1). Preferred zincxitrate ratios are from about 1:0.1 to about 1:20, more preferably from about 1:0.5 to about 1:4, more preferably from about 1:1 to about 1:3. Preferred zinc:pyro ratios are from about 1:1 to about 1:20, more preferably from about 1 :2 to about 1 :6, more preferably from about 1 :3 to about 1:5. Also preferred is a zincxitrate: pyro ratio wherein the sum of the ratio amounts of citrate and pyro is from about 3 to about 9, more preferably from about 4 to about 7, when the ratio amount of zinc is 1. The amount of zinc suitable for the purposes of this invention is from about 0.005% to about 5% Zn; more preferably from about 0.05% to about 2% Zn; more preferably still from about 0.1% to about 0.6% Zn. In dentifrice compositions, the preferred amounts of zinc are from about 0.1% to about 2%, more preferably from about 0.3% to about 0.6%. In mouthwashes, mouth rinses, mouth sprays and dental solutions, the preferred amount of zinc is from about 0.005% to about 1%, more preferably from about 0.01% to about 0.75%, more preferably still from about 0.05% to about 0.5%.
The amount of citrate anion suitable for the purposes of this invention is from about 0.015% to about 15% citrate. In dentifrice compositions, the preferred amounts of citrate anion are from about 0.2 % to about 8%, more preferably from about 0.4% to about 7%, more preferably still from about 0.6% to about 6%. In mouthwashes, mouth rinses, mouth sprays and dental solutions, the preferred amount of citrate anion is from about 0.01% to about 12%, more preferably from about 0.1% to about 6%, more preferably still from about 0.15% to about 1 %.
The amount of pyro anion suitable for the purposes of this invention is from about 0.5% to about 15% pyro. In dentifrice compositions, the preferred amounts of pyro ion are from about 1 % to about 9%, more preferably from about 2.5% to about 5%. In mouthwashes, mouth rinses, mouth sprays and dental solutions, the preferred amount of pyro anion is from about 0.01% to about 25%, more preferably from about 0.1% to about 5%.
Suitable sources of zinc ions include zinc oxide and Zn(N03)2* Zinc sources that are not suitable are zinc ethylenediaminetetraacetate (ZnEDTA) and zinc nitrilotriacetate (ZnNTA). The preferred source of zinc ions is ZnO.
Suitable sources of citrate ions include citric acid; alkali metal salts of citric acid, especially sodium citrate and potassium citrate; pharmaceutically acceptable hydrated and dehydrated salts of any of the above; and mixtures of any of the above.
Suitable sources of pyro ions are disclosed in U.S. Pat. No. 4,885,155, issued December 5, 1989 to Parran & Sakkab; U.S. Pat. No. 3,678,154, issued July 18, 1972 to Widder et al.; U.S. Pat. No. 3,737,522, issued June 5, 1973 to Francis et al.; and U.S. Pat. No. 4,627,977, issued Dedember 9, 1986 to Gaffar et al.; each is incorporated herein by reference. Suitable pyro ion sources include tetrasodium pyrophosphate, sodium acid pyrophosphate (Na2H2P2θ7), tetrapotassium pyrophosphate (K4P2O7); phosphates including, but not limited to, linear condensed polyphosphates of the general
Figure imgf000007_0001
M 's Na or κ. and n is an integer rom to ; p osphonates and diphosphonates, such as EHDP (ethane-1-hydroxy-1,1-diphosphonate) and AHP (azacyclo- heptane-2,2-diphosphonic acid); pharmaceutically-acceptable alkali metal salts of pyrophosphates, polyphosphates, phosphonates and diphosphonates; and mixtures of any of the above. Preferred polyphosphate ions are those of the above formula wherein n is 6, 13, and 21. Preferred pyro ions are pyrophosphate ions. Preferred alkali metals are sodium and potassium; mixtures of alkali metal salts are acceptable. A more preferred source of pyro ions is a potassium salt of the pyro ion.
Compositions Components of the topical, oral carrier are suitable for administration to the oral cavity of a human or other animal and are compatible with one another and the other components, especially with the Actives, used in an oral composition of this invention. The term "compatible" as used herein, means that the components are capable of being co-mingled with one another, in a manner such that there is no interaction which would substantially reduce the efficacy of the oral composition under ordinary use conditions. Preferred topical, oral carriers provide the desired characteristics for mouthwashes, mouth rinses, mouth sprays, dental treatment solutions, toothpastes, dental gels, toothpowders, prophylaxis pastes, and the like. The topical, oral carriers of this invention comprise components typically used in such compositions which are well known to a skilled practitioner. Such components include, but are not limited to, anticaries agents, antiplaque agents, anticalculus agents, dental abrasives, surfactants, flavoring agents, sweetening agents, binders, humectants, thickening agents, buffering agents, preservatives, coloring agents and pigments, ethanol and water.
The pH of oral compositions of this invention is critical but can be varied to some extent. The compositions must be at a pH which is safe for contact with the tissues of the. oral cavity, i.e. below a pH of about 9 for humans, preferably below a pH of about 8.5. Otherwise, the pH of the compositions is preferably above pH 6, more preferably above pH 7, more preferably still, above pH 7.5.
During manufacture of a composition of this invention, the conditions for addition of each component should be optimized such that the pH of the mixture does not drop below formulation pH at any time during mixing of the ingredients. To optimize stability of the final composition a pH of at least about 7.5 should be maintained at all times.
Water is a component of the topical, oral carriers of the compositions of the subject invention. Water employed in the preparation of the commercially suitable compositions should preferably be of low ion content and free of organic impurities. Water preferably comprises from about 2% to about 99%, more preferably from about 20% to about 95% of the compositions of the subject invention. When in the form of toothpaste, the compositions preferably comprise from about 20% to about 99.5%, more preferably from about 30% to about 99%, still more preferably from about 35% to about 98%, more preferably still from about 40% to about 97% water. Mouthwashes comprise preferably from about 2% to about 99.5%, more preferably from about 45% to about 99%, more preferably still from about 75% to about 98%, water.
In preparing oral compositions of this invention, it is desirable to add binders and/or thickening agents, particularly to toothpaste compositions to provide a desired consistency. Suitable binders for these compositions are those which are non-ionic at the formulation pH of the composition. By "non-ionic" is meant, not more than about 10% ionized. As used herein "formulation pH" means the pH of the final composition. Suitable binders include, but are not limited to, natural gums such as gum karaya, gum arabic, and gum tragacanth; polysaccharide gums such as xanthan gum; and other natural products such as carrageenan; chemically modified natural products such as those based on cellulose esters, that is, carboxylmethylcellulose (CMC), hydroxyethylcellulose (HEC), and hydroxypropylcellulose (HPC); and synthetic binders such as polyvinylpyrrolidone; and water soluble salts of cellulose ethers such as sodium carboxymethyl cellulose and sodium carboxymethyl hydroxyethyl cellulose. Carboxyvinyl polymer binders are less desirable, but may be used. Colloidal magnesium aluminum silicate or finely divided silica can be used as part of the thickening agent to further improve texture. Blends and mixtures of the suitable binders may significantly improve the characteristics of compositions made therewith. Preferred binders are chemically modified celluloses such as CMC or HEC; more preferred is HEC. Binders and thickening agents are generally present in the compositions of this invention in combined amounts of from about 0.1% to 10%, preferably from about 0.25% to about 7.5%, more preferably from about 0.5% to about 3.5%. Optional Components
Dental abrasives useful in the topical, oral carriers of the compositions of this invention include many different materials. The material selected must be one which is compatible with the composition of interest and does not excessively abrade dentin. These include, for example, silicas, including gels and precipitates, calcium carbonate, dicalcium orthophosphate dihydrate, calcium pyrophosphate, tricalcium phosphate, calcium polymeta-phosphate, insoluble sodium polymeta-phosphate, hydrated alumina, and resinous abrasive materials such as particulate condensation products of urea and formaldehyde, and other materials such as those disclosed by Cooley et al. in U.S. Pat. No. 3,070,510, issued December 25, 1962, incorporated herein by reference. Mixtures of abrasives may also be used.
Silica dental abrasives, of various types, can provide the unique benefits of exceptional dental cleaning and polishing performance without unduly abrading tooth enamel or dentin. For this reason they are preferred for use herein.
The silica abrasive polishing materials useful herein, as well as the other abrasives, generally have an average particle size ranging between about 0.1 and 30 microns, preferably between about 5 and 15 microns. The silica abrasive can be precipitated silica or silica gels such as the silica xerogels described in U.S. Pat. No. 3,538,230, issued March 2, 1970 to Pader et al., and in U.S. Pat. No. 3,862,307, issued June 21, 1975 to DiGiulio, both incorporated herein by reference. Preferred are the silica xerogels marketed under the tradename Syloid® by the W.R. Grace & Company, Davidson Chemical Division. Preferred precipitated silica materials include those marketed by the J. M. Huber Corporation under the tradename, Zeodent®, particularly the silica carrying the designation Zeodent 119®. These silica abrasives are described in U.S. Pat. No. 4,340,583, Wason, issued July 20, 1982, incorporated herein by reference.
Mixtures of abrasives may be used. The amount of abrasive in the compositions described herein ranges from about 6% to about 70%, preferably from about 15% to about 50%, more preferably from about 15% to about 30%, when the dentifrice is a toothpaste. Higher levels, as high as 90%, may be used if the composition is a tooth powder.
Flavoring agents can also be added to the oral compositions of this invention to make them more palatable. Suitable flavoring agents include menthol, oil of wintergreen, oil of peppermint, oil of spearmint, oil of sassafras, and oil of clove. Flavoring agents are generally included in the subject compositions in amounts of from 0% to about 3%, preferably from about 0.04% to about 2% by weight. Coloring agents may be added to compositions of this invention to improve appearance. If present, coloring agents typically are included at levels of from about 0.001% to about 0.5% by weight.
Sweetening agents are also preferred in the compositions of this invention to make them more palatable. Sweetening agents which can be used include aspartame, acesulfame, saccharin salts, dextrose, glucose, levulose thaumatin, D-tryptophan, dihydrochalcones, and cyclamate salts. Saccharin salts are preferred. Sweetening agents are generally used in the subject compositions in amounts of from 0% to about 6%, preferably from about 0.005% to about 5% by weight.
Oral compositions can also contain a surfactant. Suitable surfactants are those which are reasonably stable and form suds throughout the pH range suitable for compositions of this invention, including nonsoap anionic, nonionic, cationic, zwitterionic and amphoteric organic synthetic detergents, and compatible mixtures thereof. Many of these suitable surfactants are disclosed in U.S. Pat. No. 4,051,234, issued to Gieske et al. on September 27, 1977, and in U.S. Pat. No. 3,959,458 issued to Agricola, Briner, Granger and Widder on May 25, 1976, both of which are incorporated herein by reference. Surfactants are typically present in compositions of this invention at a level of from 0% to about 20%, preferably from about 0.1, more preferably from about 1% to about 4% by weight. Surfactants may also be used as solubilizing agents to help retain sparingly soluble components, e.g., some flavoring agents, in solutions. Surfactants suitable for this purpose include polysorbates and poloxamers.
Another optional component of the oral carriers of the compositions of this invention is a humectant. The humectant serves to keep toothpaste compositions from hardening upon exposure to air, and to give mouthwash and toothpaste compositions a moist feel to the mouth. Certain humectants can also impart desirable sweetness of flavor to mouthwash and toothpaste compositions. The humectant, on a pure humectant basis, generally comprises from 0% to about 70%, preferably from about 2% to about 55%, by weight of the compositions herein. Suitable humectants for use in compositions of this invention include edible polyhydric alcohols such as glycerin, sorbitol, xylitol, polyethylene glycol, and propylene glycol, especially sorbitol and glycerin. Preferred humectants are sorbitol and glycerin; more preferred is sorbitol.
Opacifiers may also be used in toothpastes of this invention to render the toothpaste opaque. Suitable opacifiers include titanium dioxide and some abrasives including, for example, magnesium aluminum silicate. Opacifiers generally comprise from 0% to about 4%, preferably from about 0.5% to about 3% by weight of the compositions herein. Other optional components of the compositions of this invention are preservatives. The preservatives prevent microbial growth in the compositions. Suitable preservatives include methylparaben, propylparaben, benzoates and ethanol. If the preservative is ethanol, it generally comprises from 0% to about 35% by weight, preferably from about 5% to about 15%, of the compositions herein. Other preservatives generally comprise from 0% to about 5% by weight, preferably from about 0.08% to about 2%, of the compositions herein.
Antimicrobial, antiplaque agents can also optionally be present in the oral compositions of this invention, on the condition that they are compatible with the Actives. Such agents may include, but are not limited to, triclosan, 2,4,4'-trichloro-2,-hydroxydiphenyl ether, as described The Merck Index. 11th Ed. (1989), p. 1520 (entry No. 9573); chlorhexidine, .Merck Index. No. 2090); alexidine (Merck Index. No. 222); hexetidine (Merck Index. No. 4624); sanguinarine (Merck Index. No. 8320); benzalkonium chloride (Merck Index. No. 1066); salicylanilide (Merck Index. No. 8299); domiphen bromide (Merck Index. No. 3411); cetylpyridinium chloride, (CPC) (Merck Index. No. 2024); tetradecylpyridinium chloride, (TPC); N-tetradecyl- 4-ethylpyridinium chloride (TDEPC); octenidine; delmopinol, octapinol, and other piperidino derivatives; nicin preparations; antibiotics such as augmentin, amoxicillin, tetracycline, doxycycline, minocycline, and metronidazole; and peroxides, such as cylium peroxide, hydrogen peroxide, and magnesium monoperthalate and its analogs as described in U.S. Patent No. 4,670,252; and analogs and salts of the above antimicrobial antiplaque agents. If present, the antimicrobial antiplaque agents may comprise from 0% to about 6%, preferably from about 0.1% to about 5% by weight of the compositions of this invention.
Bleaching agents can also be present in the oral compositions of this invention. Suitable bleaching agents include organic and inorganic oxidizing agents such as hydrogen peroxide, alkali metal peroxides and superoxide and organic peroxides such as monoper- oxyphthalates and perbenzoic derivatives. If present, such bleaching agents may comprise from 0% to about 6%, preferably from about 1 % to about 5% by weight of the compositions of this invention. Nutrients can also be present in the oral composition of this invention, on condition that they are compatible with the Actives. Such agents may include folate, retinoids (Vitamin A), Vitamin C, Vitamin E. If present, the nutrients generally comprise from about 0.001% to about 10% by weight of the compositions of this invention. Other optional ingredients include a safe and effective amount of a fluoride ion source, which typically is in the form of a water-soluble fluoride compound. This water-soluble fluoride compound is typically present in the compositions of this invention in an amount sufficient to give a fluoride concentration of from about 0.0025% to about 5.0% by weight, preferably from about 0.005% to about 2.0% by weight. Preferred fluoride sources are sodrum fluoride, acidulated phosphate fluoride, and sodium monofluorophosphate. U.S. Pat. No. 3,678,154, issued July 18, 1972 to Widder et al., discloses such salts as well as others, and is incorporated herein by reference. Other optional ingredients include synthetic or natural anionic polymeric polycarboxylates, polysaccharides, and polysulfates. The polymers may be present at a weight amount of from about 0.05% to about 3%, more preferably form about 0.05% to about 2%, more preferably still from about 0.1% to about 2%. Suitable polymers include but are not limited to copolmers of maleic acid anhydride or acid with another polymerizable ethylenically unsaturated monomers, linear polycarboxylates, alginates, pectins, carageenans. Most preferred are 1:4 to 4:1 copolymers of maleic anhydride or acid with another polymerizable ethylenically unsaturated monomer, preferably methyl vinyl ether (methoyethylene) having a molcular weight (M.W.) of about 30,000 to about 1,000,000. These copolymers are available for example as Gantrez® AN 139 (M.W. 500,000), A.N. 119 (M.W. 250,000) and preferably S-97 Pharmaceutical Grade (M.W. 70,000), of GAF Coφoration. Other operative polymeric polycarboxylates include those disclosed in U.S. Pat. No. 3,956,480, such as the 1:1 copolymers of maleic anhydride with ethyl acrylate, hydroxyethyl methacrylate, N- vinyl-2-pyrrolidone, or ethylene, the latter being available for example as Monsanto EMA No. 1103, M.W. 10,000, and EMA Grade 61 , and 1:1 copolymers of acrylic acid with methyl or hydroxyethyl methacrylate, methyl or ethyl acrylate, isobutyl vinyl ether or N-vinyl 2- pyrrolidone. Preferred Compositions
Preferred compositions of this invention are in the form of dentifrices, especially toothpastes. Components of toothpastes generally include a dental abrasive (from about 10% to about 50%), a surfactant (from about 0.5% to about 10%), a thickening agent (from about 0.1% to about 5%), a humectant (from about 10% to about 70%), a flavoring agent (from about 0.04% to about 2%), a sweetening agent (from about 0.1% to about 3%), a coloring agent (from about 0.01 % to about 0.5%) and water (from about 2% to about 45%). Other preferred compositions of this invention are mouthwashes, mouth sprays, and dental solutions. Components of such mouthwashes and mouth sprays include water (from about 45% to about 99%), ethanol (from 0% to about 25%), humectant (from 0% to about 50%), surfactant (from about 0.01% to about 7%), flavoring agent (from about 0.04% to about 2%), sweetening agent (from about 0.1% to about 3%), and coloring agent (from about 0.001% to about 0.5%). Such mouthwashes and mouth sprays may also include an antiplaque agent (from about 0.1% to about 5%). Methods of Use
Another aspect of this invention involves methods of treating or preventing mouth odor, dental plaque, calculus and gingivitis, by application of compositions comprising a safe and effective amount of Actives, to tissues of the oral cavity. Such compositions are described hereinabove.
These methods involve administering a safe and effective amount of Actives, preferably by administering an oral composition of this invention, as described hereinabove, to the oral cavity. Preferably methods of this invention comprise administering an amount of composition comprising at least about 0.001 g of the Actives. The teeth and other oral cavity tissues are exposed to the Actives.
When the oral composition is a toothpaste, preferably from about 0.3 grams to about 15 grams, preferably from about 0.5 grams to about 5 grams, more preferably from about 1 to about 2 grams, of toothpaste is applied to an applicating device e.g., a toothbrush. The applicating device is then contacted with the oral cavity surfaces in a manner such that the oral composition is contacted with tissue of the oral cavity, especially the teeth and gums. The applicating device may be further used to effect an even distribution of the oral composition to the tooth surface, for example by brushing. The application preferably lasts for a period of from about 15 seconds to about 10 minutes, more preferably from about 30 seconds to about 3 minutes, more preferably still from about 1 minute to about 2 minutes. Following application, the toothpaste residue is typically removed from the tooth surface by using a liquid acceptable to the oral cavity, typically water, to rinse and be expectorated from the oral cavity. When the oral composition is a mouthwash, typically from about 1 ml. to about 20 ml., preferably from about 2 ml. to about 15 ml., most preferably from about 10 ml. to about 15 ml., of liquid mouthwach containing the antiplaque Active is introduced to the oral cavity. The liquid mouthwash is then agitated for from about 10 seconds to about 10 min., preferably from about 15 seconds to about 3 min., more preferably from about 30 seconds to about 2 minutes, within the oral cavity to obtain an improved distribution of the mouthwash over the tissue of the oral cavity. Following agitation, the mouthwash is typically expectorated from the oral cavity.
Application frequency is preferably from about 3 times weekly to about 4 times daily, more preferably from about once daily to about 3 times daily, more preferably still from about once to about twice daily.
The period of treatment typically ranges from about one day to a lifetime.
Examples
The following non-limiting examples further describe and demonstrate preferred embodiments within the scope of this invention.
The examples are given solely for illustration and are not to be construed as limitations of this invention as many variations are possible without departing from the spirit and scope of this invention.
The compositions of this invention can be made using methods which are commonly used to produce oral care products.
EXAMPLES l-VI The following are examples of dentifrice compositions of this invention and are made using conventional processes. The numbers listed are weight percentages of the compositions. During manufacture, the pH is maintained at a minimum of pH 7.5.
Figure imgf000016_0001
Figure imgf000017_0001
EXAMPLE VII Following dental prophylaxis, a person brushes his teeth for sixty seconds twice daily using 1 g of a fluoride, non-anticalculus toothpaste. After eight weeks he receives dental prophylaxis performed by his dentist. For the following eight weeks the person brushes his teeth for sixty seconds twice daily with 1 g of the composition of Example I. After eight weeks, the person has significantly less calculus on his teeth than he did after the first eight weeks. EXAMPLE VIII
Following dental prophylaxis, a person brushes his teeth for sixty seconds twice daily using 1 g of a fluoride, non-anticalculus toothpaste. After one week he receives dental prophylaxis performed by his dentist. For the following week the person brushes his teeth for sixty seconds twice daily with 1 g of the composition of EΞxample IV. After one week, the person has significantly less plaque on his teeth than he did after the first week.
EXAMPLE IX Following dental prophylaxis, a person brushes his teeth for sixty seconds twice daily using 1.5 g of a fluoride, non-anticalculus toothpaste. After nine weeks he receives dental prophylaxis performed by his dentist. For the following nine weeks the person brushes his teeth for sixty seconds twice daily with 1.5 g of the composition of Example III. After nine weeks, the person has significantly less calculus on his teeth than he did after the first nine weeks.
EXAMPLES X-XIV
The following are examples of mouthwash and dental rinse compositions of this invention and are made using conventinal processes. The amounts listed are weight percentages of the compositions. During manufacture, the pH of the following
Figure imgf000018_0001
EXAMPLE XV Following dental prophylaxis, a person rinses her mouth for twenty seconds twice daily for a period of eight weeks using 10 ml of a non-anticalculus mouth rinse. After eight weeks, the person received dental prophylaxis and rinses for twenty seconds twice daily with 10 ml of the composition of Example XI. After eight weeks, the person has significantly less calculus on her teeth than she did after the first eight weeks, using the non-anticalculus mouth rinse.
EXAMPLE XVI Following dental prophylaxis, a person rinses her mouth for thirty seconds twice daily for a period of one week using 12 ml of a non-antiplaque mouth rinse. During this week, the person does not brush her teeth. At the end of one week, the person received dental prophylaxis and rinses for thirty seconds twice daily with 12 ml of the composition of Example XIII. During this week, the person does not brush her teeth. At the end of one week, the person has significantly less plaque on her teeth than she did after the first week, using the non-antiplaque mouth rinse.
EXAMPLE XVII Following dental prophylaxis, a person rinses her mouth for forty-five seconds twice daily for a period of nine weeks using 15 ml of a non-anticalculus mouth rinse. After nine weeks, the person received dental prophylaxis and rinses for forty-five seconds twice daily with 15 ml of the composition of Example XIV. After nine weeks, the person has significantly less calculus on her teeth than she did after the first nine weeks, using the non-anticalculus toothpaste.
While particular embodiments of this invention have been described, it will be obvious to those skilled in the art that various changes and modifications to these examples can be made without departing from the spirit and scope of the invention. It is intended to cover, in the appended claims, all such modifications that are within the scope of this invention.

Claims

Claims
1. An oral-care composition comprising: a) (i) zinc oxide or zinc nitrate; (ii) a source of citrate ions; and
(iii) one or more phosphorus-containing anticalculus agents selected from pyrophosphate, phosphonate, diphosphonate and pharmaceutically-acceptable linear condensed polyphosphates of the general formula: wherein n is an integer from 2 to 21 ; wherein the
Figure imgf000020_0001
zinc ionsxitrate ions is from 1 :0.1 to
1 :20, preferably from 1 :0.5 to 1 :4, more preferably from 1 :1 to 1 :3; the molar ratio of the zinc ions:phosphorus-containing anticalculus agents is from 1 :1 to 1 :20, preferably from 1 :1 to 1 :6, more preferably from 1 :3 to 1:5; and
(b) a pharmaceutically-acceptable topical oral carrier.
2. The composition of Claim 1 in the form of a dentifrice wherein the pharmaceutically acceptable topical oral carrier comprises a dental abrasive.
3. The composition of any of Claims 1-2 comprising a binder which is non-ionic at the formulation pH of the composition.
4. The composition of Claim 1 in the form of a solution selected from a mouthwash, a mouth rinse, a dental solution, and a mouth spray, wherein the pharmaceutical carrier comprises a material selected from a humectant, ethanol, and a nonionic surfactant.
5. The composition of any of Claims 1-4 wherein the pH of the composition is above pH 7; preferably above 7.5.
6. The composition of any of Claims 1-5 comprising from 0.01 % to 0.75% zinc.
7. The composition of any of Claims 1-6 wherein the anticalculus agent is selected from pyrophosphate, EHDP, AHP, and linear condensed polyphosphates of the general formula: in n
Figure imgf000021_0001
is 6, 13, or 21 , preferably the anticalcu us agent is pyrophosphate, preferably a potassium salt of pyrophosphate.
8. The composition of any of Claims 1-7 comprising from 35% to 99.5 percent water.
9. The composition of any of Claims 1-8 comprising a source of fluoride ions yielding from 0.0025% to 5% by weight fluoride ions.
10. A method for treating or preventing dental plaque, calculus or malador of the oral cavity comprising administering to the oral cavity of a human or other mammal a safe and effective amount of a composition selected from Claims 1-9.
PCT/US1993/011786 1992-12-18 1993-12-06 Oral compositions containing antiplaque, anticalculus agents WO1994014406A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
BR9307689-4A BR9307689A (en) 1992-12-18 1993-12-06 Oral compositions containing anti-plaque, anti-calculus agents
AU57399/94A AU5739994A (en) 1992-12-18 1993-12-06 Oral compositions containing antiplaque, anticalculus agents
JP6515184A JPH08504816A (en) 1992-12-18 1993-12-06 Oral composition containing antiplaque and anticalculus agent
EP94903458A EP0675705A1 (en) 1992-12-18 1993-12-06 Oral compositions containing antiplaque, anticalculus agents

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US99333692A 1992-12-18 1992-12-18
US07/993,336 1992-12-18
US14877593A 1993-11-16 1993-11-16
US08/148,775 1993-11-16

Publications (1)

Publication Number Publication Date
WO1994014406A1 true WO1994014406A1 (en) 1994-07-07

Family

ID=26846148

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/011786 WO1994014406A1 (en) 1992-12-18 1993-12-06 Oral compositions containing antiplaque, anticalculus agents

Country Status (11)

Country Link
EP (1) EP0675705A1 (en)
JP (1) JPH08504816A (en)
CN (1) CN1095262A (en)
AU (1) AU5739994A (en)
BR (1) BR9307689A (en)
CA (1) CA2151815A1 (en)
CZ (1) CZ156895A3 (en)
HU (1) HUT72042A (en)
MX (1) MX9400052A (en)
TR (1) TR27536A (en)
WO (1) WO1994014406A1 (en)

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455023A (en) * 1993-06-10 1995-10-03 Church & Dwight Co., Inc. Liquid mouthwash containing a particulate bicarbonate suspension
EP0784971A3 (en) * 1996-01-11 1999-03-24 The Procter & Gamble Company Tartar control oral compositions
US5939052A (en) * 1996-11-21 1999-08-17 The Procter & Gamble Company Dentifrice compositions containing polyphosphate and fluoride
WO1999059539A1 (en) * 1998-05-21 1999-11-25 The Boots Company Plc Odour absorbing agent
US6190644B1 (en) * 1996-11-21 2001-02-20 The Procter & Gamble Company Dentifrice compositions containing polyphosphate and monofluorophosphate
WO2002045678A2 (en) * 2000-12-05 2002-06-13 Colgate-Palmolive Company Zinc containing dentifrice of reduced astringency
US6447789B1 (en) * 1999-10-13 2002-09-10 Terrie E. Banks Facial cleanser and method of treating skin conditions
US6521216B1 (en) 1999-11-12 2003-02-18 The Procter & Gamble Company Dual phase stannous oral compositions
US6555094B1 (en) 1999-11-12 2003-04-29 The Procter & Gamble Company Stannous oral compositions
WO2003059304A1 (en) * 2002-01-03 2003-07-24 The Procter & Gamble Company Stable oral compositions comprising casein phosphopeptide complexes and flouride
US6713049B1 (en) 1999-11-12 2004-03-30 The Procter & Gamble Company Oral compositions providing optimal surface conditioning
WO2008122578A2 (en) * 2007-04-05 2008-10-16 Glaxo Group Limited Novel use
EP2057978A1 (en) 2007-11-09 2009-05-13 The Procter and Gamble Company Oral stannous compositions
US7879315B2 (en) 2002-11-19 2011-02-01 Showa Yakuhin Kako Co., Ltd. Agent for dissolving dental calculi and dental caries
US8652495B2 (en) 2010-03-31 2014-02-18 Colgate-Palmolive Company Oral care composition
US8778311B2 (en) 2006-03-22 2014-07-15 The Procter & Gamble Company Oral zinc compositions
EP2099416A4 (en) * 2006-12-22 2015-05-27 Douglas Anderson Anti-calculus dental composition and methods for using same
US9320699B2 (en) 2010-03-31 2016-04-26 Colgate-Palmolive Company Oral care composition
WO2016064412A1 (en) * 2014-10-24 2016-04-28 Colgate-Palmolive Company Preparation of zinc citrate and of zinc citrate-containing oral care compositions
WO2016100381A1 (en) * 2014-12-16 2016-06-23 Colgate-Palmolive Company Metal salt compositions
WO2016105433A1 (en) * 2014-12-26 2016-06-30 Colgate-Palmolive Company Personal care compositions with zinc phosphate active
WO2016105430A1 (en) * 2014-12-26 2016-06-30 Colgate-Palmolive Company Zinc phosphate complex
WO2016105429A1 (en) * 2014-12-26 2016-06-30 Colgate-Palmolive Company Zinc phosphate complex
WO2016105431A1 (en) * 2014-12-26 2016-06-30 Colgate-Palmolive Company Zinc phosphate complex
WO2016105432A1 (en) * 2014-12-26 2016-06-30 Colgate-Palmolive Company Zinc phosphate complex for oral care
WO2016105434A1 (en) * 2014-12-26 2016-06-30 Colgate-Palmolive Company Personal care composition with zinc phosphate active
US20160228335A1 (en) * 2015-02-05 2016-08-11 University Of Maryland, Baltimore Rechargeable calcium phosphate-containing dental materials
US10154948B2 (en) 2014-06-20 2018-12-18 Colgate-Palmolive Company Oral compositions containing zinc, stannous and fluoride ion sources
US10258549B2 (en) 1999-11-12 2019-04-16 The Procter & Gamble Company Method of protecting teeth against erosion
US10470985B2 (en) 1999-11-12 2019-11-12 The Procter & Gamble Company Method of protecting teeth against erosion
US10596086B2 (en) 2012-06-21 2020-03-24 The Procter & Gamble Company Reduction of tooth staining derived from cationic antibacterials
US11191709B2 (en) 2019-04-26 2021-12-07 The Procter & Gamble Company Reduction of tooth staining derived from cationic antimicrobials

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350438B1 (en) * 1998-02-27 2002-02-26 The Procter & Gamble Company Oral care compositions comprising chlorite and methods
US6846478B1 (en) * 1998-02-27 2005-01-25 The Procter & Gamble Company Promoting whole body health
JPH11246376A (en) * 1998-02-27 1999-09-14 Sunstar Inc Composition for oral cavity
JP2005139201A (en) * 2002-11-19 2005-06-02 Showa Yakuhin Kako Kk Agent for dissolving dental calculi and dental caries
JP3957293B2 (en) * 2003-01-27 2007-08-15 花王株式会社 Oral composition
DE10311171A1 (en) * 2003-03-12 2004-09-23 Henkel Kgaa Oral and dental care composition with antitartar, antiplaque and anti-discoloration action, containing cationic antibacterial agent, aza-cycloalkane-diphosphonic acid and xanthan gum or carboxymethyl cellulose
US20070183989A1 (en) * 2005-12-21 2007-08-09 Michael Prencipe Oral Compositions Comprising Zinc Citrate and/or Tocopherol Agents
CN101292943B (en) * 2008-06-20 2010-04-14 陕西太和科技股份有限公司 Nanometer zinc oxide toothpaste
US9968803B2 (en) 2009-10-29 2018-05-15 Colgate-Palmolive Company Low water stannous fluoride plus zinc citrate dentifrice with improved stability, rheology, and efficacy
TWI455728B (en) * 2010-01-14 2014-10-11 Colgate Palmolive Co Dentifrice compositions

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2747852A1 (en) * 1977-10-26 1979-05-03 Colgate Palmolive Co Dentifrice with improved cleansing and polishing action - contg. abrasive agent together with zinc cpd. to reduce abrasion of dental enamel
US4187288A (en) * 1975-01-28 1980-02-05 Colgate Palmolive Company Modified abrasive system for dentifrices
US4309409A (en) * 1975-12-22 1982-01-05 Stauffer Chemical Company Anti-corrosion formulation for toothpastes
EP0295116A1 (en) * 1987-06-12 1988-12-14 Unilever Plc Oral compositions
EP0396232A2 (en) * 1989-03-13 1990-11-07 Vipont Pharmaceutical, Inc. Oral rinse compositions
US5000944A (en) * 1989-06-09 1991-03-19 Colgate-Palmolive Company Zinc-containing oral products with reduced astringency

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4187288A (en) * 1975-01-28 1980-02-05 Colgate Palmolive Company Modified abrasive system for dentifrices
US4309409A (en) * 1975-12-22 1982-01-05 Stauffer Chemical Company Anti-corrosion formulation for toothpastes
DE2747852A1 (en) * 1977-10-26 1979-05-03 Colgate Palmolive Co Dentifrice with improved cleansing and polishing action - contg. abrasive agent together with zinc cpd. to reduce abrasion of dental enamel
EP0295116A1 (en) * 1987-06-12 1988-12-14 Unilever Plc Oral compositions
EP0396232A2 (en) * 1989-03-13 1990-11-07 Vipont Pharmaceutical, Inc. Oral rinse compositions
US5000944A (en) * 1989-06-09 1991-03-19 Colgate-Palmolive Company Zinc-containing oral products with reduced astringency

Cited By (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455023A (en) * 1993-06-10 1995-10-03 Church & Dwight Co., Inc. Liquid mouthwash containing a particulate bicarbonate suspension
EP0784971A3 (en) * 1996-01-11 1999-03-24 The Procter & Gamble Company Tartar control oral compositions
US5939052A (en) * 1996-11-21 1999-08-17 The Procter & Gamble Company Dentifrice compositions containing polyphosphate and fluoride
US6190644B1 (en) * 1996-11-21 2001-02-20 The Procter & Gamble Company Dentifrice compositions containing polyphosphate and monofluorophosphate
WO1999059539A1 (en) * 1998-05-21 1999-11-25 The Boots Company Plc Odour absorbing agent
US6447789B1 (en) * 1999-10-13 2002-09-10 Terrie E. Banks Facial cleanser and method of treating skin conditions
US6521216B1 (en) 1999-11-12 2003-02-18 The Procter & Gamble Company Dual phase stannous oral compositions
US10369090B2 (en) 1999-11-12 2019-08-06 The Procter & Gamble Company Method of protecting teeth against erosion
US6555094B1 (en) 1999-11-12 2003-04-29 The Procter & Gamble Company Stannous oral compositions
US10258549B2 (en) 1999-11-12 2019-04-16 The Procter & Gamble Company Method of protecting teeth against erosion
US6713049B1 (en) 1999-11-12 2004-03-30 The Procter & Gamble Company Oral compositions providing optimal surface conditioning
US10702460B2 (en) 1999-11-12 2020-07-07 The Procter & Gamble Company Method of protecting teeth against erosion
US10470985B2 (en) 1999-11-12 2019-11-12 The Procter & Gamble Company Method of protecting teeth against erosion
US10258550B2 (en) 1999-11-12 2019-04-16 The Procter & Gamble Company Method of protecting teeth against erosion
US10376451B2 (en) 1999-11-12 2019-08-13 The Procter & Gamble Company Method of protecting teeth against erosion
WO2002045678A3 (en) * 2000-12-05 2003-01-16 Colgate Palmolive Co Zinc containing dentifrice of reduced astringency
WO2002045678A2 (en) * 2000-12-05 2002-06-13 Colgate-Palmolive Company Zinc containing dentifrice of reduced astringency
WO2003059304A1 (en) * 2002-01-03 2003-07-24 The Procter & Gamble Company Stable oral compositions comprising casein phosphopeptide complexes and flouride
US7879315B2 (en) 2002-11-19 2011-02-01 Showa Yakuhin Kako Co., Ltd. Agent for dissolving dental calculi and dental caries
US8778311B2 (en) 2006-03-22 2014-07-15 The Procter & Gamble Company Oral zinc compositions
EP2099416A4 (en) * 2006-12-22 2015-05-27 Douglas Anderson Anti-calculus dental composition and methods for using same
WO2008122578A3 (en) * 2007-04-05 2009-11-12 Glaxo Group Limited Oral care composition comprising particulate zinc oxide
WO2008122578A2 (en) * 2007-04-05 2008-10-16 Glaxo Group Limited Novel use
US8906347B2 (en) 2007-11-09 2014-12-09 The Procter & Gamble Co. Oral stannous compositions
EP2057978A1 (en) 2007-11-09 2009-05-13 The Procter and Gamble Company Oral stannous compositions
US9532932B2 (en) 2010-03-31 2017-01-03 Colgate-Palmolive Company Oral care composition
US11103431B2 (en) 2010-03-31 2021-08-31 Colgate-Palmolive Company Oral care composition
US11628128B2 (en) 2010-03-31 2023-04-18 Colgate-Palmolive Company Oral care composition
US9883995B2 (en) 2010-03-31 2018-02-06 Colgate-Palmolive Company Oral care composition
US9320699B2 (en) 2010-03-31 2016-04-26 Colgate-Palmolive Company Oral care composition
US10441516B2 (en) 2010-03-31 2019-10-15 Colgate-Palmolive Company Oral care composition
US8652495B2 (en) 2010-03-31 2014-02-18 Colgate-Palmolive Company Oral care composition
US10596086B2 (en) 2012-06-21 2020-03-24 The Procter & Gamble Company Reduction of tooth staining derived from cationic antibacterials
US11253451B2 (en) 2012-06-21 2022-02-22 The Procter & Gamble Company Reduction of tooth staining derived from cationic antibacterials
US10154948B2 (en) 2014-06-20 2018-12-18 Colgate-Palmolive Company Oral compositions containing zinc, stannous and fluoride ion sources
WO2016064412A1 (en) * 2014-10-24 2016-04-28 Colgate-Palmolive Company Preparation of zinc citrate and of zinc citrate-containing oral care compositions
US11234913B2 (en) 2014-10-24 2022-02-01 Colgate-Palmolive Company Preparation of zinc citrate and of zinc citrate-containing oral care compositions
RU2706793C2 (en) * 2014-12-16 2019-11-21 Колгейт-Палмолив Компани Compositions based on metal salts
WO2016100381A1 (en) * 2014-12-16 2016-06-23 Colgate-Palmolive Company Metal salt compositions
US10357438B2 (en) 2014-12-16 2019-07-23 Colgate-Palmolive Company Metal salt compositions
AU2014415218B2 (en) * 2014-12-26 2018-05-24 Colgate-Palmolive Company Zinc phosphate complex for oral care
WO2016105432A1 (en) * 2014-12-26 2016-06-30 Colgate-Palmolive Company Zinc phosphate complex for oral care
RU2692066C2 (en) * 2014-12-26 2019-06-20 Колгейт-Палмолив Компани Zinc phosphate complex
RU2690157C2 (en) * 2014-12-26 2019-05-31 Колгейт-Палмолив Компани Zinc phosphate complex for oral care
RU2681525C2 (en) * 2014-12-26 2019-03-07 Колгейт-Палмолив Компани Compositions for personal hygiene with zinc phosphate as an active substance
AU2014415217B2 (en) * 2014-12-26 2018-11-29 Colgate-Palmolive Company Zinc phosphate complex
AU2014415216B2 (en) * 2014-12-26 2018-11-29 Colgate-Palmolive Company Zinc phosphate complex
US11690791B2 (en) 2014-12-26 2023-07-04 Colgate-Palmolive Company Zinc phosphate complex
EP3586925A1 (en) * 2014-12-26 2020-01-01 Colgate-Palmolive Company Zinc phosphate complex
AU2019201158B2 (en) * 2014-12-26 2020-02-27 Colgate-Palmolive Company Zinc phosphate complex
WO2016105434A1 (en) * 2014-12-26 2016-06-30 Colgate-Palmolive Company Personal care composition with zinc phosphate active
US10350151B2 (en) 2014-12-26 2019-07-16 Colgate-Palmolive Company Zinc phosphate complex
WO2016105433A1 (en) * 2014-12-26 2016-06-30 Colgate-Palmolive Company Personal care compositions with zinc phosphate active
US11020330B2 (en) 2014-12-26 2021-06-01 Colgate-Palmolive Company Personal care composition with Zinc phosphate active
WO2016105431A1 (en) * 2014-12-26 2016-06-30 Colgate-Palmolive Company Zinc phosphate complex
US11344486B2 (en) 2014-12-26 2022-05-31 Colgate-Palmolive Company Zinc phosphate complex
US11213466B2 (en) 2014-12-26 2022-01-04 Colgate-Palmolive Company Personal care compositions with zinc phosphate active
WO2016105429A1 (en) * 2014-12-26 2016-06-30 Colgate-Palmolive Company Zinc phosphate complex
WO2016105430A1 (en) * 2014-12-26 2016-06-30 Colgate-Palmolive Company Zinc phosphate complex
US10813849B2 (en) * 2015-02-05 2020-10-27 University Of Maryland, Baltimore Rechargeable calcium phosphate-containing dental materials
US20160228335A1 (en) * 2015-02-05 2016-08-11 University Of Maryland, Baltimore Rechargeable calcium phosphate-containing dental materials
US11191709B2 (en) 2019-04-26 2021-12-07 The Procter & Gamble Company Reduction of tooth staining derived from cationic antimicrobials
US11826452B2 (en) 2019-04-26 2023-11-28 The Procter & Gamble Company Reduction of tooth staining derived from cationic antimicrobials

Also Published As

Publication number Publication date
MX9400052A (en) 1994-07-29
JPH08504816A (en) 1996-05-28
AU5739994A (en) 1994-07-19
CA2151815A1 (en) 1994-07-07
CN1095262A (en) 1994-11-23
HUT72042A (en) 1996-03-28
BR9307689A (en) 1999-08-31
HU9501778D0 (en) 1995-08-28
EP0675705A1 (en) 1995-10-11
TR27536A (en) 1995-06-07
CZ156895A3 (en) 1996-01-17

Similar Documents

Publication Publication Date Title
WO1994014406A1 (en) Oral compositions containing antiplaque, anticalculus agents
US11406573B2 (en) Oral care compositions
US5358705A (en) Use of N-acetylated amino acid complexes in oral care compositions
WO1994014407A1 (en) Oral compositions containing antiplaque, anticalculus agents
US10524990B2 (en) Oral care compositions
CA2140874C (en) Oral compositions
JPH09503506A (en) Oral composition
AU2007269423A1 (en) High fluoride ion oral care composition and method for maintaining anticaries activity
RU2723646C1 (en) Compositions for oral care
EP0311412A2 (en) Anticalculus compositions
US5068100A (en) Anticalculus compositions
US5500206A (en) Oral compositions comprising actinomyces viscosus fimbriae
EP0311259A2 (en) Oral compositions
US4990328A (en) Anticalculus compositions
US5500208A (en) Oral compositions comprising a novel tripeptide
WO1995033764A1 (en) Oral compositions comprising a novel tripeptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR BY CA CZ FI HU JP KP KR KZ LK LV MG MN MW NO NZ PL RO RU SD SK UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1994903458

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2151815

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PV1995-1568

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1994903458

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1995-1568

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: PV1995-1568

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: 1994903458

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994903458

Country of ref document: EP